IL5 and allergic asthma: Nowadays, biological drugs approved by regulatory agencies in the United States (FDA) and Europe (EMA) are Omalizumab (MA that blocks IgE union to its receptor for allergic asthma), mepolizumab and reslizumab (anti-IL-5 MA for eosinophilic asthma), benralizumab (antagonist of the α subunit of IL-5 receptor for eosinophilic asthma), and dupilumab (directed against the α subunit of IL-4 receptor which is a common receptor for IL-4 and IL-13).